WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Thursday, November 15, 2007

Hide?	Set Name	Query	Hit Count
		DB=USPT; PLUR=YES; OP=ADJ	
☐	L1	(546/219.ccls. or 514/328.ccls.) and (depression or anxiety or apnoea or migraine)	40

END OF SEARCH HISTORY

```
=> .s  C19 H28 N2 O3/mf
L4         1376 C19 H28 N2 O3/MF

=> s l4 and piperidin?
        1236574 PIPERIDIN?
L5          277 L4 AND PIPERIDIN?

=> s l5 and piperidinedione
           4873 PIPERIDINEDIONE
L6            4 L5 AND PIPERIDINEDIONE

=> d 1-3

L6   ANSWER 1 OF 4  REGISTRY  COPYRIGHT 2007 ACS on STN
RN   732209-36-8  REGISTRY
ED   Entered STN:  24 Aug 2004
CN   2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-
     4,4-dimethyl-, (+)-  (CA INDEX NAME)
FS   STEREOSEARCH
MF   C19 H28 N2 O3
CI   COM
SR   CA

Rotation (+).
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**


L6   ANSWER 2 OF 4  REGISTRY  COPYRIGHT 2007 ACS on STN
RN   117576-37-1  REGISTRY
ED   Entered STN:  18 Nov 1988
CN   2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-
     4,4-dimethyl-, (-)-  (CA INDEX NAME)
FS   STEREOSEARCH
MF   C19 H28 N2 O3
CI   COM
SR   CA
LC   STN Files:   BEILSTEIN*, CA, CAPLUS, USPATFULL
         (*File contains numerically searchable property data)

Rotation (-).
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L6 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2007 ACS on STN
RN 117539-18-1 REGISTRY
ED Entered STN: 11 Nov 1988
CN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,5-dimethyl- (9CI) (CA INDEX NAME)
MF C19 H28 N2 O3
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> FILE REG

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	32.10	40.34

FILE 'REGISTRY' ENTERED AT 11:02:53 ON 15 NOV 2007

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 NOV 2007 HIGHEST RN 953817-57-7
DICTIONARY FILE UPDATES: 14 NOV 2007 HIGHEST RN 953817-57-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> STR 732209-36-8

:END

L7 STRUCTURE CREATED

=> S L7 FAM FUL

FULL SEARCH INITIATED 11:02:56 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 20 TO ITERATE

100.0% PROCESSED 20 ITERATIONS 13 ANSWERS
SEARCH TIME: 00.00.01

L8 13 SEA FAM FUL L7

=>

=> D SCAN

L8 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl-, sulfate (1:1)
MF C19 H28 N2 O3 . H2 O4 S

CM 1



CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):12

L8 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-1,4-Benzodiazepine-3-carboxylic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-, monopotassium salt, compd. with potassium hydroxide (K(OH)) (1:1), mixt. with 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl-2,6-piperidinedione (9CI)
MF C19 H28 N2 O3 . C16 H11 Cl N2 O3 . H K O . K
CI MXS

CM 1



CM 2

CM 3



● K

CM 4

K—OH

L8 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl-, (+)-
MF C19 H28 N2 O3
CI COM

Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl-, (-)-
MF C19 H28 N2 O3
CI COM

Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl-, monohydrochloride, (+)- (9CI)
MF C19 H28 N2 O3 . Cl H

Rotation (+).



● HCl

L8 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, compd. with 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl-2,6-piperidinedione (1:1) (9CI)
MF C23 H16 O6 . C19 H28 N2 O3

CM 1



CM 2



L8 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl-, monohydrochloride, mixt. with 7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one (9CI)
MF C19 H28 N2 O3 . C16 H13 Cl N2 O . Cl H
CI MXS

CM 1



● HCl

CM 2



L8 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl-
MF C19 H28 N2 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl-, hydrochloride (9CI)
MF C19 H28 N2 O3 . x Cl H



● x HCl

L8 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl-, monohydrochloride, (-)- (9CI)
MF C19 H28 N2 O3 . Cl H

Rotation (-).



● HCl

L8 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, compd. with (-)-3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl-2,6-piperidinedione (1:1) (9CI)
MF C23 H16 O6 . C19 H28 N2 O3

CM 1

Rotation (-).



CM 2



L8 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl-, monohydrochloride, mixt. with 7-chloro-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-amine 4-oxide, monohydrochloride (9CI)
MF C19 H28 N2 O3 . C16 H14 Cl N3 O . 2 Cl H
CI MXS

CM 1



● HCl

CM 2



● HCl

L8 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl-, hydrochloride (1:1)
MF C19 H28 N2 O3 . Cl H
CI COM



● HCl

ALL ANSWERS HAVE BEEN SCANNED

=> FILE REG

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	68.15	108.49

FILE 'REGISTRY' ENTERED AT 11:04:17 ON 15 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 NOV 2007 HIGHEST RN 953817-57-7
DICTIONARY FILE UPDATES: 14 NOV 2007 HIGHEST RN 953817-57-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> STR 117576-37-1

WARNING. STEREO DATA NOT INCLUDED IN MODEL (NOT SEARCHABLE)
:END

L9 STRUCTURE CREATED

=> S L9 FAM FUL

FULL SEARCH INITIATED 11:04:21 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 20 TO ITERATE

100.0% PROCESSED 20 ITERATIONS 13 ANSWERS
SEARCH TIME: 00.00.01

L10 13 SEA FAM FUL L9

```
     (FILE 'HOME' ENTERED AT 10:55:56 ON 15 NOV 2007)

     FILE 'REGISTRY' ENTERED AT 10:57:19 ON 15 NOV 2007
L1             1 S AGN 2979/CN

     FILE 'CAPLUS' ENTERED AT 10:57:57 ON 15 NOV 2007

     FILE 'REGISTRY' ENTERED AT 10:58:12 ON 15 NOV 2007
L2             1 S  53873-28-2
L3             1 S  117539-17-0
L4          1376 S  C19 H28 N2 O3/MF
L5           277 S L4 AND PIPERIDIN?
L6             4 S L5 AND PIPERIDINEDIONE

     FILE 'REGISTRY' ENTERED AT 11:02:53 ON 15 NOV 2007
L7                STR 732209-36-8
L8            13 S L7 FAM FUL

     FILE 'REGISTRY' ENTERED AT 11:04:17 ON 15 NOV 2007
L9                STR 117576-37-1
L10           13 S L9 FAM FUL

=> fil caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      68.15     176.64

FILE 'CAPLUS' ENTERED AT 11:05:30 ON 15 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 15 Nov 2007  VOL 147 ISS 21
FILE LAST UPDATED: 14 Nov 2007  (20071114/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l10
L11           19 L10

=> s l1
L12           15 L1

=> s l11 not l12
L13            4 L11 NOT L12

=> d bib abs hitstr 1-4

L13  ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2007 ACS on STN
```

AN 2004:182707 CAPLUS
DN 140:210809
TI Piperidin-2,6-dione pamoate salts for the treatment of stress-related affective disorders, and pharmaceutical compositions containing them
IN Wermuth, Camille Georges
PA Prestwick Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004017970	A1	20040304	WO 2003-IB3698	20030818
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2495377	A1	20040304	CA 2003-2495377	20030818
	AU 2003255947	A1	20040311	AU 2003-255947	20030818
	EP 1539160	A1	20050615	EP 2003-792588	20030818
	EP 1539160	B1	20060621		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003013674	A	20050621	BR 2003-13674	20030818
	CN 1678316	A	20051005	CN 2003-819914	20030818
	JP 2005538146	T	20051215	JP 2004-530467	20030818
	AT 330605	T	20060715	AT 2003-792588	20030818
	NZ 538341	A	20060929	NZ 2003-538341	20030818
	PT 1539160	T	20061031	PT 2003-792588	20030818
	ES 2268474	T3	20070316	ES 2003-3792588	20030818
	US 2006025443	A1	20060202	US 2005-524693	20050215
	MX 2005PA01919	A	20050603	MX 2005-PA1919	20050217
	IN 2005CN00223	A	20070907	IN 2005-CN223	20050221
	NO 2005001471	A	20050523	NO 2005-1471	20050321
PRAI	GB 2002-19639	A	20020822		
	WO 2003-IB3698	W	20030818		

OS MARPAT 140:210809
GI



I

AB Pamoate salts of certain 3-phenyl-3-dimethylaminoalkyl-4,4dimethylpiperidin-2,6-diones,(I) (R1 = MeO, EthO, OH; R2 = MeO, EthO, OH; n = 2, 3) and pharmacol. acceptable solvates thereof are devoid of the weight loss and hepatocyte changes in the rat which limited to marginally effective levels the permitted clin. doses of the corresponding

hydrochlorides in the treatment or prophylaxis of stress-related affective disorders such as anxiety, depression, migraine and sleep apnea. The preferred pamoate salts are 3(3,5dimethoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate and, especially, 3(3-methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine2,6-dione pamoate.

IT 666175-71-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(piperidin-2,6-dione pamoate salts for treatment of stress-related affective disorders, and pharmaceutical compns. containing them)

RN 666175-71-9 CAPLUS

CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, compd. with 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl-2,6-piperidinedione (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 53873-21-5
CMF C19 H28 N2 O3



CM 2

CRN 130-85-8
CMF C23 H16 O6



IT 666175-73-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(piperidin-2,6-dione pamoate salts for treatment of stress-related affective disorders, and pharmaceutical compns. containing them)

RN 666175-73-1 CAPLUS

CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, compd. with (-)-3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl-2,6-piperidinedione (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 117576-37-1
CMF C19 H28 N2 O3

Rotation (-).



CM 2

CRN 130-85-8
CMF C23 H16 O6



IT 500350-77-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(piperidin-2,6-dione pamoate salts for treatment of stress-related affective disorders, and pharmaceutical compns. containing them)
RN 500350-77-6 CAPLUS
CN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl-, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 53873-21-5
CMF C19 H28 N2 O3



CM 2

CRN 7664-93-9
CMF H2 O4 S



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:174547 CAPLUS
DN 138:204953
TI Preparation of piperidine-2,6-dione bisulfate salts useful for the treatment of stress-related affective disorders
IN Gittos, Maurice Ward
PA Fr.
SO Brit. UK Pat. Appl., 26 pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2379216	A	20030305	GB 2001-20821	20010828
	CA 2459009	A1	20030313	CA 2002-2459009	20020822
	WO 2003020275	A1	20030313	WO 2002-GB3869	20020822
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002321522	A1	20030318	AU 2002-321522	20020822
	EP 1420788	A1	20040526	EP 2002-755226	20020822
	EP 1420788	B1	20061213		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002012175	A	20040720	BR 2002-12175	20020822
	CN 1549715	A	20041124	CN 2002-816912	20020822
	JP 2005502677	T	20050127	JP 2003-524582	20020822
	NZ 531345	A	20050729	NZ 2002-531345	20020822

	AT 347891	T	20070115	AT 2002-755226	20020822
	ES 2275898	T3	20070616	ES 2002-2755226	20020822
	MX 2004PA01777	A	20041122	MX 2004-PA1777	20040225
	US 2004249159	A1	20041209	US 2004-486925	20040225
	US 7189742	B2	20070313		
	IN 2004MN00151	A	20050624	IN 2004-MN151	20040227
PRAI	GB 2001-20821	A	20010828		
	WO 2002-GB3869	W	20020822		

OS MARPAT 138:204953

GI



I

AB Title compds. [I; R1 = MeO, EtO, OH; R2 = H, R1; n = 2, 3], were prepared Thus, a cooled solution of H2SO4 in EtOH was mixed into 3-(3-methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione (AGN 2979) in EtOH followed by removal of solvent under reduced pressure and recrystn. from EtOH to give the bisulfate (II). II at 65 mg every 2 days in a 90 kg human male eliminated episodes of obstructive sleep apnea. II drug formulations are given. I are devoid of the weight loss and hepatocyte changes in the rat which limited to marginally effective levels the permitted clin. doses of the corresponding hydrochlorides in the treatment or prophylaxis of stress-related affective disorders such as anxiety, depression, migraine and sleep apnea.

IT 500350-77-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperidine-2,6-dione bisulfate salts useful for the treatment of stress-related affective disorders)

RN 500350-77-6 CAPLUS

CN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl-, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 53873-21-5
CMF C19 H28 N2 O3



CM 2

CRN 7664-93-9
CMF H2 O4 S



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1989:580731 CAPLUS
DN 111:180731
TI Anxiolytic pharmaceuticals containing 3-phenyl-3-(aminoalkyl)-4-methyl-2,6-dioxopiperidine derivatives
IN Costall, Brenda
PA National Research Development Corp., UK
SO Brit. UK Pat. Appl., 45 pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2206491	A	19890111	GB 1988-16214	19880707
	GB 2206491	B	19910123		
	EP 299680	A2	19890118	EP 1988-306208	19880707
	EP 299680	A3	19890726		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	DK 8803826	A	19890111	DK 1988-3826	19880708
	AU 8818862	A	19890112	AU 1988-18862	19880708
	AU 609496	B2	19910502		
	JP 01063517	A	19890309	JP 1988-173621	19880711
	ZA 8804986	A	19900328	ZA 1988-4986	19880711
PRAI	GB 1987-16338	A	19870710		

OS MARPAT 111:180731
GI



I

AB 3-Phenyl-3-aminoalkyl-4-methyl-2,6-dioxopiperidine derivs. (I; R1 = H, alkyl; n = 1, 2; R2 = H, Me, provided that one of R2 = H if n = 2; R3 = H, alkyl; R4 = alkyl; R5, R6 = H, Me; m = 0-3; each Y is in a meta or para position and represents OH, alkoxy, alkyl, hydroxyalkyl, halo, CF3, provided that OH and alkoxy are not in the para position) or their salts antagonize anxiogenesis associated with the withdrawal of addictive drugs, especially alc., nicotine, and cocaine. Tablets contained 3-(3'-methoxyphenyl)-3-(3"-N,N-dimethylaminopropyl)-4,4-dimethyl-2,6-dioxopiperidine (II)

(base) 1, lactose 51.5, dried maize starch 45, and Mg stearate 1.5 mg/tablet. Mice were exposed to 8% alc. in the drinking water and during alc. withdrawal they received 10 mg diazepam/kg i.p. or 0.5 mg II/kg i.p. The mice were previously kept in a darkened box and during testing placed in a test area with white and black areas; during alc. intake the mice showed anxiolysis characterized by increased exploratory behavior in the white section and when the alc. was withdrawn the reverse profile was observed Both diazepam and II not only reversed anxiogenesis but actually led to anxiolysis; both appeared to be equieffective to combat anxiogenesis in alc. withdrawal, but II was more potent and devoid of the initial sedative action seen on treatment with diazepam. Both II and diazepam antagonized anxiogenesis in cocaine withdrawal in mice or in nicotine withdrawal in marmosets. I had no action on benzodiazepine receptors.

IT 53873-21-5 117576-37-1 123323-80-8
RL: BIOL (Biological study)
(as anxiolytic, for treatment of anxiogenesis associated with addictive drug withdrawal)

RN 53873-21-5 CAPLUS
CN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl- (CA INDEX NAME)



RN 117576-37-1 CAPLUS
CN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl-, (-)- (CA INDEX NAME)

Rotation (-).



RN 123323-80-8 CAPLUS
CN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

L13 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1989:546823 CAPLUS
DN 111:146823
TI Phenyl-3-aminoalkyl-4-methyl-2,6-dioxopiperidine derivatives and their use as antipsychotic agents
IN Costall, Brenda
PA National Research Development Corp., UK
SO Eur. Pat. Appl., 14 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 298738	A2	19890111	EP 1988-306207	19880707
	EP 298738	A3	19890809		
	EP 298738	B1	19920930		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	GB 2206490	A	19890111	GB 1988-16213	19880707
	GB 2206490	B	19910918		
	AT 81003	T	19921015	AT 1988-306207	19880707
	DK 8803825	A	19890111	DK 1988-3825	19880708
	DK 170360	B1	19950814		
	AU 8818861	A	19890127	AU 1988-18861	19880708
	AU 606701	B2	19910214		
	ZA 8804937	A	19900328	ZA 1988-4937	19880708
	JP 01063516	A	19890309	JP 1988-173620	19880711
	US 4877800	A	19891031	US 1988-217450	19880711
	CA 1328077	C	19940329	CA 1988-571649	19880711
PRAI	GB 1987-16337	A	19870710		
	EP 1988-306207	A	19880707		

OS MARPAT 111:146823
GI



I

AB Phenyl-3-aminoalkyl-4-methyl-2,6-dioxopiperidine derivs. (I; R1, R3 = H, alkyl; n = 1,2; R2 = H, Me, provided that R2 = H when n = 2; R4 = alkyl; R5,R6 = H, Me; m = 0-3; Y is in a meta- or para-position; Y = OH, alkoxy, alkyl, hydroxyalkyl, halo, CF3, provided that OH and alkoxy are not in the para-position) or its salts are used for the manufacture of pharmaceuticals used in the treatment of psychosis. Hyperactivity was induced in rats via sterotaxic surgery, i.e. implantation of cannulae for intracerebral infusion of dopamine into the center of the nucleus accumbens and 25 μg dopamine was thus infused over a 24 h time period. Dopamine-induced hyperactivity occurred in a biphasic pattern between days 2-5 and 9-12 of treatment and could be antagonized with 0.01-10 mg/kg i.p. doses of 3-(3'-methoxyphenyl)-3-(3''-N,N-dimethylaminopropyl)-4,4-dimethyl-2,6-dioxopiperidine (II); a lower dose of II (0.00001 mg/kg) controlled the 2nd peak but prevented control of the 1st peak. After withdrawal of II and dopamine a rebound of hyperactivity was not observed; persistent or excessive motor depression was not observed either with II during treatment. Fluphenazine at a 0.025-0.05 mg/kg dose was also effective in controlling dopamine-induced hyperactivity, however, after withdrawal, a rebound activity was observed Tablets contained II 1, lactose 51.5, dried maize starch 45, and Mg stearate 1.5 mg each.

IT 53873-21-5 117576-37-1
RL: BIOL (Biological study)
(antipsychotic agent)

RN 53873-21-5 CAPLUS

CN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl- (CA INDEX NAME)



RN 117576-37-1 CAPLUS

CN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl-, (-)- (CA INDEX NAME)

Rotation (-).


H
N
O
O
NMe2
(CH2)3
Me
Me
MeO

```
=> s  666175-74-2 or  53873-21-5 or  92519-16-9 or   117576-37-1
             1 666175-74-2
                 (666175-74-2/RN)
             1 53873-21-5
                 (53873-21-5/RN)
             1 92519-16-9
                 (92519-16-9/RN)
             1 117576-37-1
                 (117576-37-1/RN)
L4           4 666175-74-2 OR  53873-21-5 OR  92519-16-9 OR   117576-37-1

=> d l4

L4   ANSWER 1 OF 4  REGISTRY  COPYRIGHT 2007 ACS on STN
RN   666175-74-2  REGISTRY
ED   Entered STN:  22 Mar 2004
CN   2,6-Piperidinedione, 3-(3,5-dimethoxyphenyl)-3-[3-(dimethylamino)propyl]-
     4,4-dimethyl-, (-)-  (CA INDEX NAME)
FS   STEREOSEARCH
MF   C20 H30 N2 O4
CI   COM
SR   CA
LC   STN Files:   CA, CAPLUS

Rotation (-).
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

             1 REFERENCES IN FILE CA (1907 TO DATE)
             1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> d l4 2-4

L4   ANSWER 2 OF 4  REGISTRY  COPYRIGHT 2007 ACS on STN
RN   117576-37-1  REGISTRY
ED   Entered STN:  18 Nov 1988
CN   2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-
     dimethyl-, (-)-  (CA INDEX NAME)
FS   STEREOSEARCH
MF   C19 H28 N2 O3
CI   COM
SR   CA
LC   STN Files:   BEILSTEIN*, CA, CAPLUS, USPATFULL
         (*File contains numerically searchable property data)
```

Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2007 ACS on STN
RN 92519-16-9 REGISTRY
ED Entered STN: 17 Dec 1984
CN 2,6-Piperidinedione, 3-(3,5-dimethoxyphenyl)-3-[3-(dimethylamino)propyl]-4,4-dimethyl- (CA INDEX NAME)
MF C20 H30 N2 O4
CI COM
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2007 ACS on STN
RN 53873-21-5 REGISTRY
ED Entered STN: 16 Nov 1984
CN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl- (CA INDEX NAME)
OTHER NAMES:
CN 3-[3-(Dimethylamino)propyl]-3-(m-methoxyphenyl)-4,4-dimethyl-2,6-piperidinedione
DR 117539-16-9
MF C19 H28 N2 O3
CI COM
LC STN Files: BEILSTEIN*, CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, MEDLINE,

PHAR, PROUSDDR, RTECS*, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

11 REFERENCES IN FILE CA (1907 TO DATE)
11 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> s l4
L5          12 L4

=> s l5 and weight
        150877 WEIGHT
L6           0 L5 AND WEIGHT

=> d bib abs hitstr l5 1-12

L5   ANSWER 1 OF 12  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2007:329586  CAPLUS
DN   146:330838
TI   4,4-Dimethylpiperidine-2,6-dione derivatives for use in the treatment of
     hypertension
IN   Gittos, Maurice Ward
PA   Prestwick Pharmaceuticals, Inc., USA
SO   PCT Int. Appl., 20pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   WO 2007031737         A1    20070322    WO 2006-GB3379          20060913
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
             KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
             MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
             RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
PRAI GB 2005-18763         A     20050914
OS   MARPAT 146:330838
AB   Hypertension is treated with certain 3-phenyl-3-dimethylaminoalkyl-4,4-
     dimethylpiperidin-2,6-diones.  The preferred compds. are
     3(3,5-dimethoxyphenyl)-3- (3-dimethylaminopropyl)-4,4-dimethylpiperidine-
     2,6-dione salts and, especially, 3(3- methoxyphenyl)-3-(3-dimethylaminopropyl)-
     4,4-dimethylpiperidine-2,6-dione salts.
IT   53873-21-5 92519-16-9 117576-37-1
     666175-74-2
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (dimethylpiperidinedione derivs. for treatment of hypertension)
RN   53873-21-5  CAPLUS
CN   2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-
     dimethyl-  (CA INDEX NAME)
```



RN 92519-16-9 CAPLUS
CN 2,6-Piperidinedione, 3-(3,5-dimethoxyphenyl)-3-[3-(dimethylamino)propyl]-4,4-dimethyl- (CA INDEX NAME)



RN 117576-37-1 CAPLUS
CN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl-, (-)- (CA INDEX NAME)

Rotation (-).



RN 666175-74-2 CAPLUS
CN 2,6-Piperidinedione, 3-(3,5-dimethoxyphenyl)-3-[3-(dimethylamino)propyl]-4,4-dimethyl-, (-)- (CA INDEX NAME)

Rotation (-).



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:174547 CAPLUS

DN 138:204953
TI Preparation of piperidine-2,6-dione bisulfate salts useful for the treatment of stress-related affective disorders
IN Gittos, Maurice Ward
PA Fr.
SO Brit. UK Pat. Appl., 26 pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2379216	A	20030305	GB 2001-20821	20010828
	CA 2459009	A1	20030313	CA 2002-2459009	20020822
	WO 2003020275	A1	20030313	WO 2002-GB3869	20020822
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002321522	A1	20030318	AU 2002-321522	20020822
	EP 1420788	A1	20040526	EP 2002-755226	20020822
	EP 1420788	B1	20061213		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002012175	A	20040720	BR 2002-12175	20020822
	CN 1549715	A	20041124	CN 2002-816912	20020822
	JP 2005502677	T	20050127	JP 2003-524582	20020822
	NZ 531345	A	20050729	NZ 2002-531345	20020822
	AT 347891	T	20070115	AT 2002-755226	20020822
	ES 2275898	T3	20070616	ES 2002-2755226	20020822
	MX 2004PA01777	A	20041122	MX 2004-PA1777	20040225
	US 2004249159	A1	20041209	US 2004-486925	20040225
	US 7189742	B2	20070313		
	IN 2004MN00151	A	20050624	IN 2004-MN151	20040227
PRAI	GB 2001-20821	A	20010828		
	WO 2002-GB3869	W	20020822		

OS MARPAT 138:204953
GI



I

AB Title compds. [I; R1 = MeO, EtO, OH; R2 = H, R1; n = 2, 3], were prepared Thus, a cooled solution of H2SO4 in EtOH was mixed into 3-(3-methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione (AGN 2979) in EtOH followed by removal of solvent under reduced pressure and recrystn.

from EtOH to give the bisulfate (II). II at 65 mg every 2 days in a 90 kg human male eliminated episodes of obstructive sleep apnea. II drug formulations are given. I are devoid of the weight loss and hepatocyte changes in the rat which limited to marginally effective levels the permitted clin. doses of the corresponding hydrochlorides in the treatment or prophylaxis of stress-related affective disorders such as anxiety, depression, migraine and sleep apnea.

IT 92519-16-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of piperidine-2,6-dione bisulfate salts useful for the treatment of stress-related affective disorders)

RN 92519-16-9 CAPLUS

CN 2,6-Piperidinedione, 3-(3,5-dimethoxyphenyl)-3-[3-(dimethylamino)propyl]-4,4-dimethyl- (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1992:106095 CAPLUS
DN 116:106095
TI Process for preparation of 3-aryl-3-aminoalkyl-2,6-dioxohexahydropyridines
IN Dygos, John Henry; McLaughlin, Kathleen Therese; Ng, John Sau Hoi; Paul, Kalidas
PA G.D. Searle and Co., USA
SO Eur. Pat. Appl., 15 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 448972	A2	19911002	EP 1991-102833	19910226
	EP 448972	A3	19920506		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 5104990	A	19920414	US 1990-486027	19900227
	CA 2036968	A1	19910828	CA 1991-2036968	19910225
	JP 04211657	A	19920803	JP 1991-30929	19910226
	JP 06094460	B	19941124		
	US 5220019	A	19930615	US 1992-859189	19920327
PRAI	US 1990-486027	A	19900227		

OS CASREACT 116:106095; MARPAT 116:106095
GI



I



II

AB A process is disclosed for the preparation of title compds. I [A = straight or branched C2-6 alkalene; R,R1 = C1-10 alkyl; Ar = heterocyclyl, (substituted) aryl] and particularly 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl-2,6-piperidinedione monohydrochloride (II), which is useful as an antidepressant. Thus, 6.58 Kg [(dimethylamino)propyl]methoxybenzeneacetonitrile, preparation given from 3-MeOC6H4CH2CN and Cl(CH2)3NMe2.HCl, was treated with 11.89 Kg of (Me2CH)2CHLi and then 6.25 Kg Me2C:C(CO2Et)2 in THF-heptane to give 84.69% 3-MeOC6H4C(CN)[CMe2CH(CO2Et2](CH2)3NMe2.HCl. Hydrolysis of the latter compound in refluxing 96% H2SO4 and then treatment with 29% NH4OH followed by 36% aq HCl in EtOH gave 83.5% II.

IT 53873-21-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 53873-21-5 CAPLUS

CN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl- (CA INDEX NAME)



L5 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1991:609 CAPLUS

DN 114:609

TI Low-dosage anxiolytic compositions containing dioxopiperidine derivatives

IN Costall, Brenda

PA National Research Development Corp., UK

SO S. African, 56 pp.
CODEN: SFXXAB

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	ZA 8804938	A	19900328	ZA 1988-4938	19880708
	IL 87059	A	19921201	IL 1988-87059	19880710
PRAI	GB 1987-16340	A	19870710		

OS MARPAT 114:609

GI



I

AB Dioxopiperidine derivs. I [R1 = H, C1-4 alkyl; R2 = H, Me, provided that one R2 = H when n = 2; n = 1,2; R3 = H, C1-2 alkyl; R4 = C1-2 alkyl; R5, R6 = H, Me; m = 0-3; Y = OH, C1-2 alkoxy, C1-2 (hydroxy)alkyl, halo, trifluoromethyl in a meta or para position, provided that OH and alkoxy are not in the para position] or pharmaceutically acceptable salts are low-dosage anxiolytics; pharmaceutical compns. comprise I at 10-7-10-1 mg/unit dose. 3-(3'-Methoxyphenyl)-3-(3''-N,N-dimethylethylaminopropyl)-4,4-dimethyl-2,6-dioxopiperidine (II) at 0.00001-100.0 mg/kg s.c. showed anxiolytic activity in male albino BKW mice. The effect was achieved in the absence of sedation. Tablets comprise II 0.1, lactose 51.5, maize starch 45, and Mg stearate 1.5 mg/tablet.

IT 53873-21-5 117576-37-1
RL: BIOL (Biological study)
(low-dosage anxiolytic)

RN 53873-21-5 CAPLUS

CN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl- (CA INDEX NAME)



RN 117576-37-1 CAPLUS

CN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl-, (-)- (CA INDEX NAME)

Rotation (-).



L5 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1989:580731 CAPLUS
DN 111:180731
TI Anxiolytic pharmaceuticals containing 3-phenyl-3-(aminoalkyl)-4-methyl-2,6-dioxopiperidine derivatives
IN Costall, Brenda
PA National Research Development Corp., UK
SO Brit. UK Pat. Appl., 45 pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2206491	A	19890111	GB 1988-16214	19880707
	GB 2206491	B	19910123		
	EP 299680	A2	19890118	EP 1988-306208	19880707
	EP 299680	A3	19890726		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	DK 8803826	A	19890111	DK 1988-3826	19880708
	AU 8818862	A	19890112	AU 1988-18862	19880708
	AU 609496	B2	19910502		
	JP 01063517	A	19890309	JP 1988-173621	19880711
	ZA 8804986	A	19900328	ZA 1988-4986	19880711
PRAI	GB 1987-16338	A	19870710		

OS MARPAT 111:180731
GI



I

AB 3-Phenyl-3-aminoalkyl-4-methyl-2,6-dioxopiperidine derivs. (I; R1 = H, alkyl; n = 1, 2; R2 = H, Me, provided that one of R2 = H if n = 2; R3 = H, alkyl; R4 = alkyl; R5, R6 = H, Me; m = 0-3; each Y is in a meta or para position and represents OH, alkoxy, alkyl, hydroxyalkyl, halo, CF3, provided that OH and alkoxy are not in the para position) or their salts antagonize anxiogenesis associated with the withdrawal of addictive drugs, especially alc., nicotine, and cocaine. Tablets contained 3-(3'-methoxyphenyl)-3-(3"-N,N-dimethylaminopropyl)-4,4-dimethyl-2,6-dioxopiperidine (II) (base) 1, lactose 51.5, dried maize starch 45, and Mg stearate 1.5 mg/tablet. Mice were exposed to 8% alc. in the drinking water and during alc. withdrawal they received 10 mg diazepam/kg i.p. or 0.5 mg II/kg i.p. The mice were previously kept in a darkened box and during testing placed in a test area with white and black areas; during alc. intake the mice showed anxiolysis characterized by increased exploratory behavior in the white section and when the alc. was withdrawn the reverse profile was observed Both diazepam and II not only reversed anxiogenesis but actually led to anxiolysis; both appeared to be equieffective to combat anxiogenesis in alc. withdrawal, but II was more potent and devoid of the initial sedative action seen on treatment with diazepam. Both II and diazepam antagonized anxiogenesis in cocaine withdrawal in mice or in nicotine withdrawal in marmosets. I had no action on benzodiazepine receptors.

IT 53873-21-5 117576-37-1
RL: BIOL (Biological study)
(as anxiolytic, for treatment of anxiogenesis associated with addictive drug withdrawal)
RN 53873-21-5 CAPLUS
CN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl- (CA INDEX NAME)



RN 117576-37-1 CAPLUS
CN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl-, (-)- (CA INDEX NAME)

Rotation (-).



L5 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1989:546823 CAPLUS
DN 111:146823
TI Phenyl-3-aminoalkyl-4-methyl-2,6-dioxopiperidine derivatives and their use as antipsychotic agents
IN Costall, Brenda
PA National Research Development Corp., UK
SO Eur. Pat. Appl., 14 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 298738	A2	19890111	EP 1988-306207	19880707
	EP 298738	A3	19890809		
	EP 298738	B1	19920930		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	GB 2206490	A	19890111	GB 1988-16213	19880707
	GB 2206490	B	19910918		
	AT 81003	T	19921015	AT 1988-306207	19880707
	DK 8803825	A	19890111	DK 1988-3825	19880708

	DK 170360	B1	19950814		
	AU 8818861	A	19890127	AU 1988-18861	19880708
	AU 606701	B2	19910214		
	ZA 8804937	A	19900328	ZA 1988-4937	19880708
	JP 01063516	A	19890309	JP 1988-173620	19880711
	US 4877800	A	19891031	US 1988-217450	19880711
	CA 1328077	C	19940329	CA 1988-571649	19880711
PRAI	GB 1987-16337	A	19870710		
	EP 1988-306207	A	19880707		

OS MARPAT 111:146823

GI



I

AB Phenyl-3-aminoalkyl-4-methyl-2,6-dioxopiperidine derivs. (I; R1, R3 = H, alkyl; n = 1,2; R2 = H, Me, provided that R2 = H when n = 2; R4 = alkyl; R5,R6 = H, Me; m = 0-3; Y is in a meta- or para-position; Y = OH, alkoxy, alkyl, hydroxyalkyl, halo, CF3, provided that OH and alkoxy are not in the para-position) or its salts are used for the manufacture of pharmaceuticals used in the treatment of psychosis. Hyperactivity was induced in rats via sterotaxic surgery, i.e. implantation of cannulae for intracerebral infusion of dopamine into the center of the nucleus accumbens and 25 μg dopamine was thus infused over a 24 h time period. Dopamine-induced hyperactivity occurred in a biphasic pattern between days 2-5 and 9-12 of treatment and could be antagonized with 0.01-10 mg/kg i.p. doses of 3-(3'-methoxyphenyl)-3-(3''-N,N-dimethylaminopropyl)-4,4-dimethyl-2,6-dioxopiperidine (II); a lower dose of II (0.00001 mg/kg) controlled the 2nd peak but prevented control of the 1st peak. After withdrawal of II and dopamine a rebound of hyperactivity was not observed; persistent or excessive motor depression was not observed either with II during treatment. Fluphenazine at a 0.025-0.05 mg/kg dose was also effective in controlling dopamine-induced hyperactivity, however, after withdrawal, a rebound activity was observed Tablets contained II 1, lactose 51.5, dried maize starch 45, and Mg stearate 1.5 mg each.

IT 53873-21-5 117576-37-1
RL: BIOL (Biological study)
(antipsychotic agent)

RN 53873-21-5 CAPLUS

CN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl- (CA INDEX NAME)



RN 117576-37-1 CAPLUS
CN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl-, (-)- (CA INDEX NAME)

Rotation (-).



L5 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1989:540496 CAPLUS
DN 111:140496
TI 2,6-Piperidinediones as analgesics
IN Roberts, Malcolm Henry Traffod
PA National Research Development Corp., UK
SO Eur. Pat. Appl., 22 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 295836	A2	19881221	EP 1988-305317	19880610
	EP 295836	A3	19890719		
	EP 295836	B1	19920902		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	GB 2205745	A	19881221	GB 1988-13796	19880610
	GB 2205745	B	19900919		
	AT 80035	T	19920915	AT 1988-305317	19880610
	AU 8817676	A	19881222	AU 1988-17676	19880614
	AU 606424	B2	19910207		
	US 4871750	A	19891003	US 1988-206273	19880614
	DK 8803282	A	19881217	DK 1988-3282	19880615
	ZA 8804275	A	19890530	ZA 1988-4275	19880615
	JP 01016763	A	19890120	JP 1988-149237	19880616
PRAI	GB 1987-14033	A	19870616		
	GB 1987-14374	A	19870619		
	EP 1988-305317	A	19880610		

OS MARPAT 111:140496
GI



I

AB Phenyl-3-(aminoalkyl)-4-methyl-2,6-piperidinediones I (R1 = H, C1-4 alkyl; R2 = H, Me with one R2 = H when n = 2; R3 = H, Me, Et; R4 = Me, Et; R5, R6 = H, Me; Y = OH, MeO, EtO, Me, Et, HOCH2, hydroxyethyl, halo, CF3; n = 1, 2; m = 0-3 with each Y in a meta or para position) or their salts are useful as analgesics. Using the tail-flick latency test, (-)-3-(3-methoxyphenyl)-3-[3-(dimethylamino)propyl]-4,4-dimethyl-2,6-piperidinedione [(-)-II] injected into rats at 2 mg/kg had a strong analgesic effect with the peak response delayed until 20 min after the injection and baseline latencies were not recovered until 2 h after the injection; the potency was of the same order of magnitude as morphine with a similar time course of effect. Naloxone, known to block drug actions at opioid receptors, failed to reduce the potency of this compound Tablets contained II 50, lactose 51.5, dried corn starch 45, and Mg stearate 1.5 mg/tablet.

IT 53873-21-5 117576-37-1
RL: BIOL (Biological study)
(analgesic pharmaceuticals containing)

RN 53873-21-5 CAPLUS
CN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl- (CA INDEX NAME)



RN 117576-37-1 CAPLUS
CN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl-, (-)- (CA INDEX NAME)

Rotation (-).



L5 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1988:622491 CAPLUS
DN 109:222491
TI Anxiolytic compositions containing dioxopiperidine derivatives
IN Gittos, Maurice Ward; Costall, Brenda
PA National Research Development Corp., UK
SO Eur. Pat. Appl., 34 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 263594	A2	19880413	EP 1987-307860	19870904
	EP 263594	A3	19890802		
	EP 263594	B1	19920624		
	R: BE, CH, DE, ES, FR, GB, IT, LI, LU, NL, SE				
	GB 2181346	A	19870423	GB 1986-21577	19860908
	GB 2181346	B	19891004		
	GB 2196251	A	19880427	GB 1987-20813	19870904
	GB 2196251	B	19900704		
	CA 1316112	C	19930413	CA 1987-546240	19870904
	DK 8704654	A	19880309	DK 1987-4654	19870907
	AU 8778109	A	19880310	AU 1987-78109	19870907
	AU 602716	B2	19901025		
	JP 63101361	A	19880506	JP 1987-225124	19870908
	AU 9059784	A	19901101	AU 1990-59784	19900724
PRAI	GB 1986-21577	A	19860908		
	GB 1987-16339	A	19870710		
	GB 1985-22455	A	19850911		
	GB 1986-3909	A	19860217		
	GB 1986-3910	A	19860217		
	GB 1987-16359	A	19870710		

OS MARPAT 109:222491
GI



I

AB A pharmaceutical composition in unit dose form comprises, with a pharmaceutically acceptable diluent or carrier, 10-7-10-1 mg/unit dose of 3-phenyl-3-aminoalkyl-4-methyl-2,6-dioxopiperidines I (R1 = H, C1-4 alkyl; n = 1,2; R2 = H, Me, provided that one R2 = H when n = 2; R3 = H, C1-2 alkyl; R4 = C1-2 alkyl; R5, R6 = H, Me; m = 0-3; Y = OH, C1-2 alkoxy, C1-2 alkyl, C1-2 hydroxyalkyl, halo, CF3, in meta or para position, provided that OH and alkoxy are not in para position) or pharmaceutically acceptable salts for treatment of anxiety. Native male albino BKW mice in an anti-anxiety test were administered 3(3'-methoxyphenyl)-3(3''-N,N-dimethylaminopropyl)-4,4-dimethyl-2,6-dioxopiperidine (II) in water by s.c. injection or diazepam in PEG and water by i.p. injection. II was as effective as diazepam and, in fact, was exceptionally potent (0.00001-100.0 mg/kg) and showed a dose range of 10 million (106). The dose related effects of II contrasted with the all-or-none response of diazepam. A gelatin capsule formulation comprised II HCl 2.5 and talc 70 mg/capsule.

IT 53873-21-5 92519-16-9 117576-37-1
RL: BIOL (Biological study)
(anxiolytic)

RN 53873-21-5 CAPLUS
CN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl- (CA INDEX NAME)



RN 92519-16-9 CAPLUS
CN 2,6-Piperidinedione, 3-(3,5-dimethoxyphenyl)-3-[3-(dimethylamino)propyl]-4,4-dimethyl- (CA INDEX NAME)



RN 117576-37-1 CAPLUS
CN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl-, (-)- (CA INDEX NAME)

Rotation (-).



L5 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1987:605181 CAPLUS
DN 107:205181
TI Use of dioxopiperidine derivatives in the treatment of anxiety, for the reduction of abnormally high brain levels of serotonin or 5-hydroxyindoleacetic acid, and in the treatment of bacterial or viral infections
IN Gittos, Maurice Ward
PA National Research Development Corp., UK
SO Eur. Pat. Appl., 38 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 216555	A2	19870401	EP 1986-306920	19860908
	EP 216555	A3	19891123		
	EP 216555	B1	19920902		
	R: BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	EP 452765	A2	19911023	EP 1991-105508	19860908
	EP 452765	A3	19920610		
	R: BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	DK 8604337	A	19870312	DK 1986-4337	19860910
	JP 62061919	A	19870318	JP 1986-213704	19860910
	US 4738973	A	19880419	US 1986-905525	19860910
	AU 8662601	A	19870312	AU 1986-62601	19860911
	AU 588365	B2	19890914		
	CA 1273879	A1	19900911	CA 1986-518034	19860911
	US 4835151	A	19890530	US 1987-136996	19871223
	US 4918084	A	19900417	US 1989-323308	19890314
	US 4994475	A	19910219	US 1989-452343	19891219
PRAI	GB 1985-22455	A	19850911		
	GB 1986-3909	A	19860217		
	GB 1986-3910	A	19860217		
	US 1986-905525	A3	19860910		
	US 1987-136996	A3	19871223		
	US 1989-323308	A3	19890314		

OS MARPAT 107:205181
GI



I

AB The title compds. I (R1 = OMe, OEt, OH; R2 = H, OMe, OEt, OH; R3 = Me, Et; R4, R5 = H, Me; n = 2, 3) or their pharmacol. acceptable acid addition salts are used in medications for treatment of anxiety or to counter the anxiogenic activity of benzodiazepine inverse agonists. They are also used for reduction of chronic high brain levels of serotonin or 5-hydroxyindoleacetic acid, or treatment of bacterial or viral infections. A tablet contained from I (R1 = OMe, R2 = R5 = H, R3 = R4 = Me, n = 3) (II) 100, Tranxene 10, wheat starch 7, lactose 20, and Mg stearate 1 mg. The anxiolytic activity of II in rats was between the activity of chlorodiazepoxide and diazepam, and its sedative effect was less than that of the benzodiazepines. In clin. tests the combination of II and Tranxene decreased anxiety in hospitalized depressive patients. At 120 mg/day, II stopped sleep apnea in a male patient.

IT 53873-21-5
RL: BIOL (Biological study)
(pharmaceutical, for treatment of anxiety)

RN 53873-21-5 CAPLUS

CN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl- (CA INDEX NAME)



L5 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1984:577535 CAPLUS

DN 101:177535

TI Treatment of migraine with dioxopiperidine derivatives

IN Gittos, Maurice W.; Amey, David A.

PA USA

SO U.S., 5 pp.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4461771	A	19840724	US 1983-471099	19830301
PRAI	US 1983-471099		19830301		

GI



I

AB Migraine is treated or prevented with I derivs. (R1 and R2 = H, MeO, EtO, or HO, R3 = Me or Et and n = 2 or 3) or their salts. I(R1 = MeO, R2 = H, R3 = Me, n = 3).HCl (II) [53873-28-2] was prepared by intramol.condensation of Et 4-(3-N,N-dimethylaminopropyl)-4-cyano-4-(3-methoxyphenyl)-3,3-dimethylbutanoate [53873-27-1] by refluxing in 2.5N HCl. Tablets were prepared containing 50 mg II each.

IT 53873-21-5P 92519-16-9P
RL: PREP (Preparation)
(preparation of, for migraine headache pharmaceuticals)

RN 53873-21-5 CAPLUS

CN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl- (CA INDEX NAME)



RN 92519-16-9 CAPLUS

CN 2,6-Piperidinedione, 3-(3,5-dimethoxyphenyl)-3-[3-(dimethylamino)propyl]-4,4-dimethyl- (CA INDEX NAME)



L5 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1975:564204 CAPLUS

DN 83:164204

OREF 83:25774h,25775a

TI Alkyl esters, dialkyl amides, and saturated heterocyclic amides of 4-aminoalkyl-4-cyano-4-phenylbutanoic and -but-2-enoic acids

IN Gittos, Maurice W.; Amey, David A.

PA Aspro-Nicholas Ltd., UK
SO Ger. Offen., 36 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2459077	A1	19750703	DE 1974-2459077	19741213
	GB 1458537	A	19761215	GB 1973-58202	19741203
	AU 7476155	A	19760610	AU 1974-76155	19741206
	ZA 7407769	A	19760825	ZA 1974-7769	19741206
	US 3998965	A	19761221	US 1974-531556	19741211
	BE 823272	A1	19750612	BE 1974-151436	19741212
	NL 7416161	A	19750617	NL 1974-16161	19741212
	DK 7406522	A	19750825	DK 1974-6522	19741213
	FR 2254329	A1	19750711	FR 1974-41315	19741216
	JP 50089343	A	19750717	JP 1974-144360	19741216
	US 4035497	A	19770712	US 1976-679165	19760422
PRAI	GB 1973-58202	A	19731215		
	GB 1972-59761	A	19721228		
	US 1973-425876	A2	19731218		
	US 1974-531556	A3	19741211		

GI For diagram(s), see printed CA Issue.

AB Butenoate I, isolated as the H oxalate, was prepared by treating NaH and m-MeOC6H4CH(CN)CH2CH2NMe2 in Me2SO with PhSO2OCEt:C(CO2Et)2. Butanoic acid derivative II (R = R1 = R2 = Me, R3 = H, R4 = OEt, n = 3) (III) was prepared from m-MeOC6H4CH(CN)(CH2)3NMe2 and 3,3-dimethyl-1-ethoxyprop-2-enylidenemorpholinium tetrafluoroborate. II (R = PhCH2, Me; R1, R2 = H or Me; R3 = Me or H; R4 = morpholino, n = 2 or 3) were prepared from IV and the appropriate morpholinium tetrafluoroborate. II (R = R1 = R3 = Me, R2 = H, R4 = morpholino, n = 2) was prepared by treating Me2NCH2CH2C(CN)(C6H4OMe-m)CHMeCMe:C(OEt)R5 (R5 = morpholino) with MeSO3H and NaI in EtOH. I and III were cyclized to hydropyridines with NH3. I and II have antidepressant and cardiovascular activity (no data).

IT 53873-21-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 53873-21-5 CAPLUS
CN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl- (CA INDEX NAME)



L5 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1974:520488 CAPLUS
DN 81:120488
OREF 81:19043a,19046a
TI Antidepressant 3-(aminoalkyl)-3-phenyl-2,6-dioxopiperidines or -tetrahydropyridines
IN Gittos, Maurice W.; Amey, David A.
PA Aspro-Nicholas Ltd.

SO Ger. Offen., 52 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2363052	A1	19740711	DE 1973-2363052	19731219
	DE 2363052	C2	19880721		
	AU 7363761	A	19750619	AU 1973-63761	19731218
	US 3963729	A	19760615	US 1973-425876	19731218
	ZA 7309598	A	19741127	ZA 1973-9598	19731220
	BE 808958	A1	19740621	BE 1973-139144	19731221
	GB 1455687	A	19761117	GB 1972-59761	19731227
	FR 2212147	A1	19740726	FR 1973-46908	19731228
	JP 49094683	A	19740909	JP 1974-4486	19731228
	JP 60053014	B	19851122		
	US 4035497	A	19770712	US 1976-679165	19760422
PRAI	GB 1972-59761	A	19721228		
	GB 1973-58202	A	19731215		
	US 1973-425876	A2	19731218		
	US 1974-531556	A3	19741211		

GI For diagram(s), see printed CA Issue.

AB About 20 hydrogenated pyridines I (n = 2 or 3; R = Me2N, Et2N, or PhCH2NMe; R1 = H, 3-MeO, or 4-Cl; R2 = H, Me, or Et; R3 = H or Me; R4 = H, Me, or CO2Et) and II (R5 = Me or Et; R6 = H or CO2Et) or their salts were prepared I had antidepressant and minor parasympatholytic activity when tested i.p. in the rat. Thus, 3-MeOC6H4CH(CN)(CH2)nNMe2 (III, n = 3) was treated with NaH in Me2SO and with 4-(1-ethoxy-3,3-dimethyl-2-propenylidene)morpholinium tetrafluoroborate to give 3-MeOC6H4C(CN)[(CH2)3NMe2]CMe2CH:CR7 - OEt (R7 = morpholino), which was cyclized in H2SO4 and AcOH at 100° to give I (n = 3, R = Me2N, R1 = 3-MeO, R2 = R3 = Me, R4 = H). III (n = 2) was treated with NaH in Me2SO and with PhSO3CEt:C(CO2Et)2 to give 3-MeOC6H4C(CN)(CH2CH2NMe2)CEt:C(CO2Et)2, which on treatment with H2SO4 and AcOH at 100° gave II (R5 = Et, R6 = CO2Et).

IT 53873-21-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 53873-21-5 CAPLUS

CN 2,6-Piperidinedione, 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl- (CA INDEX NAME)